بدائل البحث:
small decrease » small increased (توسيع البحث)
يعرض 701 - 720 نتائج من 2,638 نتيجة بحث عن '(( ((automatic decrease) OR (dramatic decrease)) ) OR ( ((somatic decrease) OR (small decrease)) ))', وقت الاستعلام: 0.40s تنقيح النتائج
  1. 701
  2. 702
  3. 703
  4. 704
  5. 705
  6. 706
  7. 707
  8. 708
  9. 709
  10. 710
  11. 711
  12. 712

    Table 3_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx حسب Joanna Palade (17712960)

    منشور في 2025
    "…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …"
  13. 713

    Table 7_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx حسب Joanna Palade (17712960)

    منشور في 2025
    "…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …"
  14. 714

    Image 1_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.jpg حسب Joanna Palade (17712960)

    منشور في 2025
    "…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …"
  15. 715

    Table 8_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx حسب Joanna Palade (17712960)

    منشور في 2025
    "…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …"
  16. 716

    Table 4_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx حسب Joanna Palade (17712960)

    منشور في 2025
    "…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …"
  17. 717

    Table 6_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx حسب Joanna Palade (17712960)

    منشور في 2025
    "…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …"
  18. 718

    Table 2_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx حسب Joanna Palade (17712960)

    منشور في 2025
    "…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …"
  19. 719

    Table 1_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx حسب Joanna Palade (17712960)

    منشور في 2025
    "…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …"
  20. 720

    Image 2_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.jpg حسب Joanna Palade (17712960)

    منشور في 2025
    "…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …"